口服依托泊苷治疗难治性转移性乳腺癌的疗效及安全性

发布时间：2018-04-20 14:57

  本文选题：依托泊苷 + 乳腺肿瘤　； 参考：《肿瘤防治研究》2017年05期

【摘要】：目的评价口服依托泊苷治疗转移性乳腺癌的疗效和不良反应。方法回顾性分析88例接受口服依托泊苷治疗的转移性乳腺癌患者资料。口服依托泊苷50 mg/d,d1~20,每28天为一周期。结果共纳入88例乳腺癌患者,83.0%(73/88)为三线以上治疗,78.4%(69/88)既往用蒽环类、紫杉类药物及卡培他滨治疗过。88例患者采用口服依托泊苷方案中位化疗5周期,均可评价疗效,其中部分缓解(PR)7例(8.0%),疾病稳定(SD)50例(56.8%),疾病进展(PD)31例(35.2%),无完全缓解(CR)患者。客观缓解率(CR+PR)为8.0%,临床获益率(CR+PR+SD≥6.0月)为44.3%。整体中位无进展生存期(PFS)为5.0月(95%CI:3.8~6.2月),中位生存期(OS)为17.0月(95%CI:11.3~22.7月)。主要不良反应为1~2级恶心18例(20.5%),1~2级中性粒细胞减少19例(21.6%),3级中性粒细胞减少3例(3.4%)。结论口服依托泊苷治疗难治性转移性乳腺癌耐受性好、有一定疗效。
[Abstract]:Objective to evaluate the efficacy and adverse effects of oral etoposide in the treatment of metastatic breast cancer. Methods 88 patients with metastatic breast cancer received oral etoposide therapy were retrospectively analyzed. Oral etoposide 50 mg / d 1 C 20, every 28 days for a cycle. Results A total of 88 breast cancer patients (83.0% / 88) were treated with anthracyclines (78.489% / 88), yew drugs and capecitabine for 5 cycles of oral etoposide regimen (median chemotherapy). Among them, there were 7 cases of PRD with partial remission, 50 cases of SDN with disease stability and 56.8%, and 31 cases with PDD with no complete remission. The objective remission rate (CR) was 8.0 and the clinical benefit rate (CR PR SD 鈮，

本文编号：1778233